Cholestasis is bile formation and/or bile flow impairment that manifests as fatigue, pruritus and jaundice.
It can be classified into intrahepatic or extrahepatic cholestasis.
Extrahepatic cholestasis develops from mechanical blockage in the duct system or hepatocellular defects.
Intrahepatic cholestasis may be due to functional defects hepatocellularly or from obstructive lesions of the intrahepatic biliary tract distal from the bile canaliculi.
The goal of treatment for portal hypertension varies depending on the different stages and substages of cirrhosis, and hence, pharmacological therapies for managing portal hypertension should be considered in the context of other complications of cirrhosis, according to a presentation at the recent APASL 2017 held in Shanghai, China recently.
In children with McAcune Albright Syndrome (MAS), neonatal cholestasis heals naturally, but subsequent mass lesions seem common and may be harmful, according to a retrospective study presented at the European Society for Paediatric Gastroenterology, Hepatology and Nutrition 49th Annual Meeting.
Ursodeoxycholic acid (UDCA) and S-adenosylmethionine (SAMe) both safe and effective in the management of intrahepatic cholestasis of pregnancy as presented in a multi-centered randomised controlled trial.
Infants delivered via caesarean section may be at increased risk of developing acute lymphoblastic leukaemia, according to a US study. Altered microbiota colonization is a possible explanation for this risk, although clear biological mechanisms have yet to be established.
Taking marine-derived omega-3 fatty acid (FA) supplements does not appear to protect participants from coronary heart disease (CHD) and major vascular events, regardless of history of vascular disease, lipid levels, statin use, or diabetes, suggests a recent meta-analysis.